Loading...
•
Dec 31, 2022
Arbutus Q4 2022 Earnings Report
Arbutus reported fourth quarter and year end 2022 financial results and provided a corporate update.
Key Takeaways
Arbutus Biopharma Corporation reported its fourth quarter and year end 2022 financial results. The company highlighted progress in advancing its proprietary programs in chronic HBV and Coronavirus. They ended the year with $184.3 million in cash, cash equivalents and investments.
Advanced proprietary programs in chronic HBV and Coronavirus.
AB-729 data from multiple Phase 2a combination clinical trials expected in 2023.
Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023.
Initiate Phase 1 clinical trial for oral Mpro coronavirus candidate, AB-343, expected in the second half of 2023.
Forward Guidance
Arbutus expects a net cash burn between $95 to $100 million in 2023 and believes its cash runway will be sufficient to fund operations into the fourth quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...